Blood: Effect of human-derived Fc receptor non-binding anti-CD3 monoclonal antibodies in T-ALL

T-cell acute lymphoblastic leukemia (T-ALL) is an invasive malignant tumor that accounts for about 20% of ALL casesIntensive chemotherapy regimens have a cure rate of more than 85%, but less than 50% for adults, so we need to find new treatment strategiesAlthough immunotherapy has greatly improved the treatment of B-ALL and other B-cell malignancies, they have not yet been applied to T-ALLQuang et alfound that humanized non-FcgR-binding CD3 monoclonal antibodies had anti-leukemia properties in the CD3-T-ALL heterogeneous transplantation (PDX) modelIn addition, these antibodies, in combination with chemotherapy, can improve the effects of leukemia and host survivalBecause these antibodies show only mild controlled side effects in the body, they offer a new treatment option for T-ALLQuang et alalso showed that in T-ALL PDX, the anti-leukemia properties of anti-CD3 monoclonal antibodies were largely non-dependent on Fcg receptor-mediated pathways